Clinical Trials Browser

Active not recruiting × Carcinoma, Non-Small-Cell Lung × Cyclophosphamide × Clear all

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05334329 2025-10-15

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Phase 1 Active not recruiting

6 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05492682 2025-09-05

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Phase 1 Active not recruiting

15 enrolled

BreastDermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

57 enrolled

GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

6 enrolled

BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03836352 2022-03-31

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Phase 2 Active not recruiting

184 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Ovarian Neoplasms

Clinical Trials

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors